The immune changes induced by TKIs and IFN-α in patients with CML have not been investigated previously and have important translational implications to optimize clinical trials of TKI discontinuation. This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.